Compare Bank of America Corp (BAC) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of America Corp vs BIO-TECHNE Corp — how do they compare? Bank of America Corp trades at $64.05 (market cap $446.56B), while BIO-TECHNE Corp trades at $72.15 (market cap $11.24B). The key difference: Bank of America Corp is far larger — about 39.7× BIO-TECHNE Corp's market cap, and Bank of America Corp pays the higher dividend (2%). Which is the better fit depends on your goals.
| BAC | TECH | |
|---|---|---|
Market Cap | $446.56B | $11.24B |
Volume | 55,637,172 | — |
Sector | Financials | Health |
52-Week High | $63.86 | $72.29 |
52-Week Low | $46.16 | $43.31 |
Dividend Yield | 2% | 0.44% |
Enterprise Value | — | $11.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bank of America (BAC) trades at $63.17, up 0.27% today, with strong technical momentum indicated by bullish moving averages. The company demonstrates solid fundamental performance with Q2 2026 EPS beating expectations at $1.21 versus $1.13, marking the third consecutive quarterly beat. Revenue growth accelerated to $113.1 billion in 2025, with net income reaching $30.51 billion. Recent developments include strategic partnerships with FIFA and continued investment in talent acquisition.
BAC presents a compelling investment case with analyst consensus strongly favoring buy ratings (64.82%) and a $67.36 price target offering 6.6% upside. The bank's massive deposit franchise and improving net interest margins support earnings growth. Key risks include sensitivity to interest rate changes and potential regulatory changes from upcoming stress tests. The stock's current valuation at 14.59 P/E appears reasonable given earnings momentum.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of America Corp
Bank of America Corporation operates as a financial holding company. The Company offers saving accounts, deposits, mortgage and construction loans, cash and wealth management, certificates of deposit, investment funds, credit and debit cards, insurance, mobile, and online banking services. Bank of America serves customers worldwide.
Read more on BAC →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
